Intellia Therapeutics Inc’s filing revealed that its VP, Chief Accounting Officer Dube Michael P unloaded Company’s shares for reported $16711.0 on Jan 03 ’25. In the deal valued at $12.18 per share,1,372 shares were sold. As a result of this transaction, Dube Michael P now holds 45,640 shares worth roughly $0.47 million.
Then, BASTA JAMES sold 7,074 shares, generating $86,161 in total proceeds. Upon selling the shares at $12.18, the EVP, General Counsel now owns 74,497 shares.
Before that, Lebwohl David sold 9,557 shares. Intellia Therapeutics Inc shares valued at $116,404 were divested by the EVP, Chief Medical Officer at a price of $12.18 per share. As a result of the transaction, Lebwohl David now holds 87,666 shares, worth roughly $0.89 million.
Goldman downgraded its Intellia Therapeutics Inc [NTLA] rating to a Neutral from a a Buy in a research note published on February 23, 2024; the price target was decreased to $32 from $136. A number of analysts have revised their coverage, including Wolfe Research’s analysts, who began to cover the stock in mid February with a ‘”a Peer perform”‘ rating. Canaccord Genuity began covering NTLA with “Buy” recommendation on April 13, 2023. Bernstein started covering the stock on March 21, 2023. It rated NTLA as “an Outperform”.
Price Performance Review of NTLA
On Friday, Intellia Therapeutics Inc [NASDAQ:NTLA] saw its stock fall -15.14% to $10.20. Over the last five days, the stock has lost -16.53%. Intellia Therapeutics Inc shares have fallen nearly -12.52% since the year began. Nevertheless, the stocks have fallen -65.18% over the past one year. While a 52-week high of $34.87 was reached on 01/07/25, a 52-week low of $11.34 was recorded on 01/10/25. SMA at 50 days reached $13.92, while 200 days put it at $20.64.
Levels Of Support And Resistance For NTLA Stock
The 24-hour chart illustrates a support level at 9.61, which if violated will result in even more drops to 9.02. On the upside, there is a resistance level at 11.11. A further resistance level may holdings at 12.02. The Relative Strength Index (RSI) on the 14-day chart is 29.86, which indicates oversold technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at -0.39, which suggests price will go down in the next trading period. Percent R suggests that price movement has been bearish at 92.08%. Stochastics %K at 25.31% indicates the stock is a holding.
How much short interest is there in Intellia Therapeutics Inc?
A steep rise in short interest was recorded in Intellia Therapeutics Inc stocks on 2024-12-13, growing by 3.44 million shares to a total of 19.81 million shares. Yahoo Finance data shows the prior-month short interest on 2024-11-15 was 16.37 million shares. There was a rise of 17.38%, which implies that there is a positive sentiment for the stock.
